Meeting
2023 ASCO Annual Meeting
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.
Authors
Ryan Huu-Tuan Nguyen
Department of Hematology Oncology University of Illinois of Chicago College of Medicine, Chicago, IL
Ryan Huu-Tuan Nguyen , Lucia Notardonato , Alicia Hulbert , Apurva Mallisetty , Frank Weinberg , Israel Rubinstein , Irene Juson , Cindy Chan , Li C. Liu , Zhengjia Chen , Lawrence Eric Feldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05613413
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9151)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9151
Abstract #
TPS9151
Poster Bd #
133a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2018 ASCO Annual Meeting
A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.
First Author: Marcia S. Brose
Poster
2023 ASCO Annual Meeting
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
First Author: Rajwanth Veluswamy